Literature DB >> 6331552

Quality control in the production of an immunoglobulin for intravenous use.

A Gardi.   

Abstract

This paper briefly surveys the control measures and tests which are carried out before, during and after manufacture of an i.v. immunoglobulin in order to assure the quality of the preparation. The quality requirements are determined by both the standards expected by physicians and patients and by the specifications of the registration authorities in the various countries. A great deal of know-how and considerable technical investment is required to match these requirements. Furthermore a comprehensive quality assurance programme is compulsory: It begins with the careful collection and analysis of each single blood donation, continues through all the manufacturing stages and ends with the rigorous testing of every batch of the end product - an examination comprising 23 different tests.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331552     DOI: 10.1007/bf00319960

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  6 in total

1.  Intravenous administration of human gamma-globulin.

Authors:  S BARANDUN; P KISTLER; F JEUNET; H ISLIKER
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

2.  Transmission of hepatitis B by immune serum globulin.

Authors:  E Tabor; R J Gerety
Journal:  Lancet       Date:  1979-12-15       Impact factor: 79.321

3.  In vivo behaviour of gamma globulin preparations.

Authors:  A Morell; B Schürch; D Ryser; F Hofer; F Skvaril; S Barandun
Journal:  Vox Sang       Date:  1980       Impact factor: 2.144

4.  IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A.

Authors:  F Skvaril; B Roth-Wicky; S Barandun
Journal:  Vox Sang       Date:  1980       Impact factor: 2.144

5.  [Immunoglobulin substitution in the treatment of neonatal septicemia].

Authors:  D Sidiropoulos; U Böhme; G von Muralt; A Morell; S Barandun
Journal:  Schweiz Med Wochenschr       Date:  1981-10-31

6.  Removal of hepatitis-B-virus infectivity from factor-IX complex by hepatitis-B immune-globulin. Experiments in chimpanzees.

Authors:  E Tabor; D L Aronson; R J Gerety
Journal:  Lancet       Date:  1980-07-12       Impact factor: 79.321

  6 in total
  2 in total

1.  Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis.

Authors:  Michele M Estabrook; Gary A Jarvis; J McLeod Griffiss
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

2.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.